Lantheus (NASDAQ: LNTH) will present new radiodiagnostic data at the 2026 SNMMI Annual Meeting in Los Angeles from May 30 – June 2, 2026.
Presentations cover PSMA-PET with Piflufolastat F18 in prostate cancer management and 18F-GP1 PET/CT for diagnosing acute deep vein thrombosis.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – LNTH
-1.69%
5 alerts
-1.69%Session close to close
+2.4%Peak in 4 min
$6.68BMarket Cap
1.3xRel. Volume
In the May 21 session, LNTH declined 1.69%, reflecting a mild negative market reaction.
Argus tracked a peak move of +2.4% during that session.
Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
This announcement adds further clinical and imaging depth through SNMMI presentations on PSMA-PET wi...
Analysis
This announcement adds further clinical and imaging depth through SNMMI presentations on PSMA-PET with piflufolastat F18 and 18F-GP1 PET/CT for acute deep vein thrombosis. It follows recent milestones including FDA approval of PYLARIFY TruVu and solid Q1 2026 results. Investors may focus on how these datasets reinforce Lantheus’s radiodiagnostic franchise, future regulatory interactions, and eventual integration of new imaging techniques into clinical practice and commercial offerings.
Key Figures
Meeting dates:May 30 – June 2, 2026Presentation time:June 1, 2026, 10:30–11:15 am PTPoster number:#262453+4 more
FDA approval of PYLARIFY TruVu, a new PSMA PET imaging formulation for broader access.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
LNTH has shown strong positive moves on major catalysts like FDA approvals and earnings beats, while routine conference or timing updates have produced flat-to-slightly-negative reactions.
Recent Company History
Over the past few months, LNTH has combined solid fundamentals with steady clinical and regulatory progress. FDA approval of PYLARIFY TruVu on Mar 6, 2026 saw a 10.27% gain, and Q1 2026 results on May 7 with $377.3M revenue and higher EPS drove a 5.63% rise. In contrast, standard updates like ASCO data presentations, a PDUFA date extension to Jun 29, 2026, and earnings call logistics had minimal or slightly negative impact. Today’s SNMMI data fits into this ongoing stream of clinical and imaging evidence generation.
Key Terms
snmmi, psma-pet, piflufolastat f18, pet/ct, +4 more
8 terms
snmmimedical
"radiodiagnostic data to be presented at the 2026 Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting"
SNMMI is the Society of Nuclear Medicine and Molecular Imaging, a professional organization for doctors, scientists and companies involved in medical imaging that uses tiny radioactive tracers and molecular techniques to diagnose and treat disease. Its guidelines, training and consensus statements help determine how quickly new imaging tests and therapies are adopted, reimbursed and regulated—similar to how a safety-rating organization affects the market for a new car—so its positions can influence investment prospects for related medical technologies.
psma-petmedical
"Impact of PSMA-PET with Piflufolastat F18 on Prostate Cancer Management"
A PSMA-PET scan is a medical imaging test that uses a tiny radioactive tracer that sticks to a protein commonly found on prostate cancer cells, allowing a PET scanner to highlight tumors and metastases like a GPS map for cancer. It matters to investors because it can change how accurately disease is detected and staged, influence treatment choices, and drive demand, reimbursement and sales for imaging agents, scanners and related services.
piflufolastat f18medical
"Impact of PSMA-PET with Piflufolastat F18 on Prostate Cancer Management"
A radioactive imaging agent used in PET scans to locate prostate cancer cells by binding to a specific protein on those cells, helping doctors see where disease is inside the body. It matters to investors because approval, adoption, or reimbursement of such a diagnostic can drive demand for imaging services and related products, affect clinical decision-making and downstream treatment sales, and signal commercial and regulatory prospects for the companies involved.
pet/ctmedical
"Diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis"
A PET/CT is a combined medical imaging test that overlays two scans—PET, which shows metabolic activity like a heat map of how tissues use energy, and CT, which shows detailed body structure like a map of roads and buildings. Investors care because PET/CT scans are widely used to diagnose and monitor diseases, guide treatment decisions, and support clinical trials, affecting demand for imaging equipment, hospital services, and diagnostic-related revenue streams.
deep vein thrombosismedical
"for acute deep vein thrombosis of the lower extremities in symptomatic patients"
Deep vein thrombosis is a blood clot that forms in a deep vein, most often in the leg, which can block blood flow and cause pain, swelling or more serious complications if the clot travels to the lungs. Investors care because DVT influences demand for diagnostics, drugs and devices, affects healthcare costs and liability risks, and can change the commercial prospects of companies developing prevention or treatment—like a highway blockage that disrupts traffic and downstream businesses.
phase 2medical
"a phase 2, open-label, non-randomized study"
Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.
open-labelmedical
"a phase 2, open-label, non-randomized study"
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
non-randomizedmedical
"a phase 2, open-label, non-randomized study"
Non-randomized describes a study or trial where participants are assigned to treatments or groups by a deliberate method—such as medical criteria, patient choice, or investigator decision—rather than by chance. For investors, non-randomized results can be less reliable because the groups may differ in important ways, making it harder to tell whether an outcome is caused by the treatment or by preexisting differences; think of comparing two classrooms chosen by teacher preference rather than by flipping a coin.
BEDFORD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced new radiodiagnostic data to be presented at the 2026 Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, taking place May 30 – June 2, 2026 in Los Angeles, CA.
Presentation details are as follows:
Date & Time: Monday, June 1, 2026, 10:30 am – 11:15 am PT
Session Number: MTA06 – Screen 29 Title: Impact of PSMA-PET with Piflufolastat F18 on Prostate Cancer Management for Patients with Low or Ultra-low Prostate-Specific Antigen Levels after Definitive Treatment. Presenter: Neal Shore, Carolina Urologic Research Center Poster Number: #262453
Date & Time: Tuesday, June 2, 2026, 9:50 am – 10:00 am PT Session Type: Oral Presentation
Session Title: Prognosis and Novel Imaging Techniques Session Number: SS30
Location: SS Room 2
Title: Diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis of the lower extremities in symptomatic patients: a phase 2, open-label, non-randomized study Presenter: Sangwon Han, Asan Medical Center, University of Ulsan College of Medicine
About Lantheus Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Contacts:
Lantheus Mark Kinarney Vice President, Investor Relations 978-671-8842 ir@lantheus.com
What radiodiagnostic data will Lantheus (NASDAQ: LNTH) present at the 2026 SNMMI Annual Meeting?
Lantheus will present new radiodiagnostic data on PSMA-PET with Piflufolastat F18 and 18F-GP1 PET/CT. According to Lantheus, these presentations focus on prostate cancer management and imaging for acute deep vein thrombosis in symptomatic patients.
When is Lantheus presenting PSMA-PET with Piflufolastat F18 data at SNMMI 2026?
Lantheus will present PSMA-PET with Piflufolastat F18 data on Monday, June 1, 2026, from 10:30 am to 11:15 am PT. According to Lantheus, the poster is part of the Oncology Clinical Diagnosis and Therapy Scientific Session MTA06 – Screen 29.
What is the focus of Lantheus’ 18F-GP1 PET/CT presentation at SNMMI 2026?
The 18F-GP1 PET/CT presentation focuses on diagnostic performance for acute deep vein thrombosis of the lower extremities in symptomatic patients. According to Lantheus, this is a phase 2, open-label, non-randomized study presented in the Prognosis and Novel Imaging Techniques session.
Who will present Lantheus’ PSMA-PET with Piflufolastat F18 prostate cancer data at SNMMI 2026?
Neal Shore from Carolina Urologic Research Center will present the PSMA-PET with Piflufolastat F18 poster. According to Lantheus, the work examines prostate cancer management in patients with low or ultra-low PSA levels after definitive treatment.
Who is presenting the 18F-GP1 PET/CT deep vein thrombosis study for Lantheus at SNMMI 2026?
Sangwon Han from Asan Medical Center, University of Ulsan College of Medicine, will present the 18F-GP1 PET/CT study. According to Lantheus, this oral presentation occurs in SS Room 2 during Session SS30 on Tuesday, June 2, 2026.
Where and when is the Lantheus 18F-GP1 PET/CT oral presentation scheduled at SNMMI 2026?
The 18F-GP1 PET/CT oral presentation is scheduled for Tuesday, June 2, 2026, from 9:50 am to 10:00 am PT. According to Lantheus, it will take place in SS Room 2 during Session SS30 at the Los Angeles meeting.
